Lilly Posts Higher Drug Sales, Plans to Increase Dividend

Updated on
  • Diverse pipeline will help revenue growth over next decade
  • Adjusted earnings of 86 cents a share match analyst estimates

Eli Lilly CEO: Getting Back to Annual Dividend Increase

Eli Lilly & Co. posted second-quarter earnings that matched analysts’ estimates as revenue surged, led by growing U.S. sales of the company’s top drugs such as the erectile dysfunction pill Cialis and the diabetes treatment Humalog.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.